Adami H O, Pontén J, Sparén P, Bergström R, Gustafsson L, Friberg L G
Cancer Epidemiology Unit, University Hospital, Uppsala, Sweden.
Cancer. 1994 Jan 1;73(1):140-7. doi: 10.1002/1097-0142(19940101)73:1<140::aid-cncr2820730124>3.0.co;2-2.
Cytologic screening can reduce mortality from cervical cancer by detection and removal of premalignant lesions. Conceivably, mortality is further reduced because more women with invasive disease are diagnosed at an earlier, curable stage. This hypothesis can be assessed in Sweden, where population-based screening programs were introduced successively over about a decade starting in 1964.
Record linkages permitted complete follow-up through 1986 of all 17,377 patients with invasive cervical cancer diagnosed in Sweden from 1960 through 1984. We analyzed relative survival rates that describe the survival of patients after elimination of the effects of causes of death other than cancer of the cervix.
Prognosis improved substantially in patients younger than age 50 years at diagnosis; from 1960-1964 to 1980-1984, the 5-year relative survival rate increased from 69.8% to 88.8% at age 20-29 years, from 71.7% to 85.5% at age 30-39 years, and from 68.6% to 77.9% at age 40-49 years. The excess mortality was thus reduced by more than half in patients diagnosed when younger than 40 years. In contrast, only slight or no improvement was noted in those diagnosed at older ages when screening was less extensive. In all time periods, a strong association was found between older age at diagnosis and poorer prognosis.
Although alternative explanations for our findings must be seriously considered, the most obvious interpretation is that cytologic screening reduces mortality from cervical cancer by earlier diagnosis of invasive disease.
细胞学筛查可通过检测和切除癌前病变降低宫颈癌死亡率。可以想象,由于更多患有浸润性疾病的女性在更早的可治愈阶段被诊断出来,死亡率会进一步降低。这一假设可在瑞典进行评估,该国从1964年开始在大约十年内相继推行了基于人群的筛查计划。
通过记录链接,对1960年至1984年在瑞典诊断出的所有17377例浸润性宫颈癌患者进行了直至1986年的完整随访。我们分析了相对生存率,该指标描述了消除宫颈癌以外的死亡原因影响后患者的生存情况。
诊断时年龄小于50岁的患者预后有显著改善;从1960 - 1964年到1980 - 1984年,20 - 29岁年龄组的5年相对生存率从69.8%提高到88.8%,30 - 39岁年龄组从71.7%提高到85.5%,40 - 49岁年龄组从68.6%提高到77.9%。因此,40岁以下诊断出的患者超额死亡率降低了一半以上。相比之下,在筛查范围较窄时诊断出的老年患者仅略有改善或没有改善。在所有时间段内,均发现诊断时年龄较大与预后较差之间存在密切关联。
尽管必须认真考虑对我们研究结果的其他解释,但最明显的解释是,细胞学筛查通过早期诊断浸润性疾病降低了宫颈癌死亡率。